<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844062</url>
  </required_header>
  <id_info>
    <org_study_id>SBNK-2016-015-01</org_study_id>
    <nct_id>NCT02844062</nct_id>
  </id_info>
  <brief_title>Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>A Safety and Efficacy Study of Autologous Chimeric Antigen Receptor Engineered T Cells Redirected to EGFRvIII in Patients With Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Sanbo Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Marino Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Sanbo Brain Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chimeric antigen receptor (CAR)-modified T cells can mediate long-term durable remissions in&#xD;
      recurrent or refractory CD19+ B cell malignancies, and are a promising therapy to treat&#xD;
      glioblastoma, which is the most dangerous and aggressive form of brain cancer. EGFRvIII&#xD;
      mutation (epidermal growth factor receptor variant III, EGFRvIII) is the results of tumor&#xD;
      specific gene rearrangement naturally happened in about 30% of glioblastoma patients and&#xD;
      produces a mutated protein with neo-antigen that is tumor specific and is not expressed in&#xD;
      normal human tissues. Therefore, EGFRvIII is an attractive target for CAR T cell therapy. We&#xD;
      have constructed a lentiviral vector that contains a chimeric antigen receptor that&#xD;
      recognizes the EGFRvIII tumor antigen. A truncated EGFR (tEGFR) which lacks of the ligand&#xD;
      binding domain and cytoplasmic kinase domain of wildtype EGFR is incorporated into the CAR&#xD;
      vector and is used for in vivo tracking and ablation of CAR T cells in necessary. This pilot&#xD;
      study is to determine the safety and efficacy of autologous anti-EGFRvIII CAR T cells in&#xD;
      patients with recurrent glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of infusion of autologous anti-EGFRvIII CAR T cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria.</measure>
    <time_frame>2 years</time_frame>
    <description>incidents of treatment related adverse events as assessed by CTCAE V4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Responses Rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>defined as the proportion of patients who achieved complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CAR T cells in patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proliferation of CAR T cells in patients</measure>
    <time_frame>2 years</time_frame>
    <description>CAR T cell proliferation in patients is monitored by flow or qPCR</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>anti-EGFRvIII CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti-EGFRvIII CAR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-EGFRvIII CAR T cells</intervention_name>
    <description>CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.</description>
    <arm_group_label>anti-EGFRvIII CAR T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>250 mg/m^2 d1-3</description>
    <arm_group_label>anti-EGFRvIII CAR T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25mg/m^2 d1-3</description>
    <arm_group_label>anti-EGFRvIII CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. abilities to understand and the willingness to provide written informed consent;&#xD;
&#xD;
          2. patients are ≥ 18 and ≤ 70 years old;&#xD;
&#xD;
          3. recurrent glioblastoma patients with measurable tumors. Patients have received&#xD;
             standard care of medication, such as Gross Total Resection with concurrent&#xD;
             Radio-chemotherapy (~54 - 60 Gy, TMZ). Patients must either not be receiving&#xD;
             dexamethasone or receiving ≤ 4 mg/day at the time of leukopheresis;&#xD;
&#xD;
          4. Malignant cells are EGFRvIII positive confirmed by IHC, quantitative PCR or&#xD;
             sequencing;&#xD;
&#xD;
          5. karnofsky performance score (KPS) ≥ 60;&#xD;
&#xD;
          6. life expectancy &gt;3 months;&#xD;
&#xD;
          7. satisfactory bone marrow, liver and kidney functions as defined by the following:&#xD;
             absolute neutrophile count ≥ 1500/mm^3; hemoglobin &gt; 10 g/dL; platelets &gt; 100000&#xD;
             /mm^3; Bilirubin &lt; 1.5×ULN; alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &lt; 2.5×ULN; creatinine &lt; 1.5×ULN;&#xD;
&#xD;
          8. peripheral blood absolute lymphocyte count must be above 0.8×10^9/L;&#xD;
&#xD;
          9. satisfactory heart functions;&#xD;
&#xD;
         10. patients must be willing to follow the orders of doctors;&#xD;
&#xD;
         11. women of reproductive potential (between 15 and 49 years old) must have a negative&#xD;
             pregnancy test within 7 days of study start. Male and female patients of reproductive&#xD;
             potential must agree to use birth control during the study and 3 months post study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. a prior history of gliadel implantation 4 weeks before this study start or antibody&#xD;
             based therapies;&#xD;
&#xD;
          2. HIV positive;&#xD;
&#xD;
          3. hepatitis B infection or hepatitis C infection;&#xD;
&#xD;
          4. history of autoimmune disease, or other diseases require long-term administration of&#xD;
             steroids or immunosuppressive therapies;&#xD;
&#xD;
          5. history of allergic disease, or allergy to CAR T cells or study product excipients;&#xD;
&#xD;
          6. patients already enrolled in other clinical study;&#xD;
&#xD;
          7. patients, in the opinion of investigators, may not be eligible or not able to comply&#xD;
             with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhixiong Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanbo Brain Hospital Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhixiong Lin, MD</last_name>
    <phone>+86-10-13905918963</phone>
    <email>lzx1967@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sanbo Brain Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100093</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhixiong Lin, MD</last_name>
      <phone>+86-10-13905918963</phone>
      <email>lzx1967@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

